Best of The In Vivo Blog, April 2010
Executive Summary
Best of the blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog.
You may also be interested in...
Health Care Reform: For Biopharmas There Is Much To Like
The passage of health reform was a momentous juncture for the health care industry, but is also just the beginning of years of policy development that amend or define the crucial details of the 2010 proposals. Analysts are still tallying the reform bill's final cost to biopharma companies; even so, the industry stands to gain more it gives up with the landmark legislation's passing.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.